Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
New acute myeloid leukemia research from C.A. Ortmann and co-researchers described
October 7th, 2008
According to recent research published in the journal Annals of Hematology, "PRAME is a tumor-associated antigen, which belongs to the family of cancer-testis antigens (CTA). The expression of CTA is mainly restricted to the testis and various tumors." "In contrast to other CTA, PRAME expression is also frequently detected in acute and chronic leukemias. Due to this expression pattern, PRAME has attracted great interest as a prognostic tumor marker that can be used for the detection of minimal residual disease and as a potential target for immunotherapy. In acute myeloid leukemia (AML), PRAME expression has been observed in 30-64% of cases. To evaluate whether...
Source: Cancer Weekly (2008-10-07)
|
